The effects of SGLT2 inhibitors on CRF in patients with established HF have been only minimally investigated,9, 10 and, to date, no randomized controlled trials comparing the effects of SGLT2 inhibitors on CRF with other glucose‐lowering agents have been performed. The gene discussed is SLC5A2; the disease is hydrops fetalis.